How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

View on ClinicalTrials.gov ↗

At a glance

What the study gets you: Access to the study treatment being tested
Type of study: Interventional (receives a drug or procedure)
Time in hospital: In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention: Povetacicept (drug), Tacrolimus (drug)
How long the study runs: Study runs about 39 months (dates as stated)
About the drug or intervention: Povetacicept — drug: Solution for Subcutaneous Injection. · Tacrolimus — drug: Capsules for Oral Administration.
Patient visit burden: Not specified by the sponsor

Type of study: Testing a treatment
Ages: 18 Years to 75 Years
Who: All
Number of participants: 176
Started: 2025-09-30
Last checked: 2026-09

Plain English Summary

What is this study?

• Testing a new treatment for primary membranous nephropathy
• Phase2/Phase3 - 176 participants
• The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN)

Who can take part?

• Ages 18 Years to 75 Years
• Diagnosed with primary membranous nephropathy

Where?

• Derby - University Hospital of Derby and Burton NHS Foundation Trust - Royal Derby Hospital
• Doncaster - Doncaster and Bassetlaw Hospitals NHS Foundation Trust - Doncaster Royal Infirmary
• Edinburgh - NHS Lothian - Royal Infirmary of Edinburgh
• London - Imperial College Healthcare NHS Trust - Hammersmith Hospital
• +2 more UK sites

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).

Primary Membranous Nephropathy

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search

Age· Tell us your age for better matching

Gender· Tell us your sex for better matching

Still need:

• Tell us your age for better matching
• Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

Age: 18 Years - 75 Years
Who can join: All genders

What the study is looking for

✓Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a...

Who cannot take part

✗Hypersensitivity to investigational medicinal product or to any of its excipients
✗Other protocol defined Inclusion/Exclusion criteria will apply

See the full criteria

Key Inclusion Criteria: • Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility Key Exclusion Criteria: • Hypersensitivity to investigational medicinal product or to any of its excipients Other protocol defined Inclusion/Exclusion criteria will apply